ELEDON PHARMACEUTICALS INC (ELDN)
US28617K1016 - Common Stock
ChartMill assigns a Buy % Consensus number of 85% to ELDN. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 12.75. This target is 210.6% above the current price.
ELDN was analyzed by 12 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about ELDN.
In the previous month the buy percentage consensus was at a similar level.
ELDN was analyzed by 12 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-11-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-04 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-07 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-03-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-11-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-10-24 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-09-27 | Noble Capital Markets | Initiate | Outperform |
| 2023-08-22 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-05-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2022-06-01 | SVB Leerink | Maintains | Outperform |
| 2021-11-24 | HC Wainwright & Co. | Maintains | Buy |
| 2021-04-27 | SVB Leerink | Maintains | Outperform |
| 2021-03-23 | Cantor Fitzgerald | Initiate | Overweight |
| 2021-02-08 | SVB Leerink | Initiate | Outperform |